Search Results
Pennsylvania Adoptees Longitudinal Study (PALS)
This study will examine various factors within the home of children adopted from the child welfare system between the ages of 4 and 10 that may impact their development. The first visit will occur remotely via Penn State Health Microsoft Teams; the second visit is optional and will occur within 4 weeks of the first visit at the Transforming Lives of Children Center in Harrisburg, PA; and the third visit will occur one year after the first visit, when research staff will travel to participants' homes. This research will help understand the factors that impact the development of children adopted from the child welfare system and how we may better serve these children and their families.
The child and parent will be asked to complete interviews, questionnaires and various tasks. Parents may also be asked to complete questionnaires online.Participation will last for one year and include the following:-One visit occurring remotely via PSH Microsoft Teams-One visit at the Transforming the Lives of Children Center in Harrisburg, PA, four weeks after Zoom visit (optional)-Final visit at home will occur one year after the first Zoom visit
$225
Child legally adopted by the caregiver
The same caregiver will participate in each of the visits
A biological parent resides in the same home as the child
A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C mutation (MRT849-001)
This study is to determine the maximum tolerated dose (MTD) of MRTX849 using one or more dosing regimens. The regimens includ using MRTX849 or in combination with Afatinib, Cetuximab, or Pembrolizumab. The study will also look at how it can be tolerated MRTX849 when its taken with food.
If you take part in this research, your major responsibilities will include: •Keep your study appointments and complete all study assessments. If you cannot keep anappointment, please contact study personnel (your study doctor or study staff) as soon aspossible to schedule a new appointment.•Inform your study personnel about any symptoms, changes in medications, doctor's or nurse'sappointments, or hospital admissions that you may have had.•Agree to not participate in any other clinical research study•Inform study personnel if you believe you or your partner might be pregnant•Inform study personnel if you change your mind about participating in the study.•Inform your other doctors that you are taking part in this study.•Avoid grapefruit and grapefruit juice.•Avoid herbal medications and preparations including but not limited to St. John’s wort, Kava,turmeric/curcumin, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA),yohimbe (yohimbine), saw palmetto, and ginseng.•Avoid medications that are processed by liver enzymes, your doctor will counsel you on these.•Avoid medications known to have risk of changing the electrical activity in the heart, your doctorwill council you on these.•For your safety, you must tell the study doctor or nurse about all the prescription drugs, herbalproducts, over-the-counter drugs (OTC), vitamins and other supplements you are taking.Check with the study doctor before starting any new medicines (including prescription, OTCdrugs, vitamins and herbal supplements) or changing doses of medications that you arealready taking.
Unresectable or metastatic disease.
Presence of tumor lesions to be evaluated per RECIST 1.1:
Life expectancy of at least 3 months.
Eastern Cooperative Oncology Group (ECOG) performance status in 0 or 1.
Patients with carcinomatous meningitis
History of significant hemoptysis or hemorrhage within 4 weeks of the first dose date
Undergone major surgery within 4 weeks of first dose date
History of intestinal disease or major gastric surgery likely to alter absorption of study treatment or inability to swallow oral medications
A Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of STAR-0215 in Participants with Hereditary Angioedema (The ALPHA-STAR Trial)
The main purpose of the study is to evaluate the safety and tolerability of an injection of the study drug in participants with Hereditary Angioedema. This study is open-label, which means that everyone in the study will receive the study drug and no participant will receive a placebo.
The study will last approximately for one year, with a total of approximately 11-16 study site visits. You will have your blood drawn at every study site visit, urine collected, pregnancy test if applicable, and receive study drug. You will also complete questionnaires and be contact weekly by the study site.
Documented diagnosis of HAE type I or II.
Experienced at least 4 HAE attacks within the 12 months prior to screening.
Negative pregnancy test at screening visit
Experience at least 2 HAE attacks during the Run-In period.
Active liver disease
History of drug or alcohol abuse in the 12 months prior to screening
Pregnant or breastfeeding
Use of medications prescribed for the prevention of HAE attacks prior to screening: lanadelumab within 90 days, berotralstat within 21 days, all other prophylactice therapies within 7 days.
Athletes' Experiences in Sport
In this study, we are interested in learning about how male athletes think about and understand the experience and expression of emotion in competitive sports.
Competitive athlete
Penn State student
18+ years
Non-athlete
Non-student
Under 18 years
Women and Infants' Stress and Health
The goal of this study is to understand how babies and their mothers learn to respond to stress during the early years of the baby's life. Participating women complete questionnaires and do a mildly stressful task alone (during pregnancy) or with their babies (at four different times over the first two years of the baby's life) and collect saliva samples that tell us about stress responses, either at home or at one of our lab sites. We aim to use what we learn to better support expecting parents who may be at risk for stress-related health problems and improve their children's resilience to stress throughout life.
Women are asked to participate in six sessions over Zoom and/or at the PACT Center between their 28th week of pregnancy and when their child is 2 years old. During these sessions, which last up to 2 hours each, mothers and babies will1.participate in mildly stressful tasks (like having the mother leave the room for up to 3 minutes and then return) and games to assess the baby’s emotional and cognitive development2.provide saliva samples by drooling into a tube (for the mother) or holding a cotton swab in their baby’s mouth to get it wet3.fill out questionnaires about themselves and their baby4.take part in clinical interviews that ask about mood and other markers of psychological ill-being
$220
18 or older
English speaking
Autonomic Control of the Circulation and the Venous Distension Reflex
This study is looking at how blood pressure control is altered by increased volume in veins.
Fluent in written and spoken English
Capable of giving informed consent
Free of acute or chronic medical conditions such as hypertension, heart disease, lung disease, neuromuscular disease, kidney disease, diabetes or cancer
Able to visit Penn State Health Milton S. Hershey Medical Center in Hershey, Pa. for study visits
Pregnant or nursing
Currently using opioids or undergoing treatment for opioid use disorder
Living with a chronic disease such as hypertension, heart disease, lung disease, neuromuscular disease, kidney disease, diabetes or cancer
Visceral Pain Sensation and Nav1.8
We wish to investigate the role of a specific gene in visceral pain sensation and perception. This gene, Nav1.8 has a known change present in 10% of the population which may affect the way we feel inflammatory pain in the gut. This is an important symptom in inflammatory bowel disease (IBD). Some patients feel high levels of pain we would like to control, other patients feel little to no pain in the presence of very active disease, which can lead to dangerously under-treated disease. In this study, we will use healthy volunteers as well as IBD patients, and test their sensitivity using rectal balloon dilation.Research subjects will be asked to fast, skipping solid foods and opaque liquids for 6 hours before the testing. Usually this means skipping 1 meal. At the beginning of the study visit. they will use an over the counter enema to clear their rectum of any stool. Healthy control subjects that have never had a colonoscopy before and all IBD patients will undergo a very brief proctoscopy to either verify rectal health or check for any IBD disease activity. Healthy controls that have had a prior colonoscopy within the last 5 years will skip that prior step. Then a trained physician on the research team will insert a thin, lubricated tube into the rectum, which will be inflated to specific pressures. Most of these tests will be designed to measure any change in sensation, then the need to use the toilet, followed by urgent need or discomfort, and lastly the lower threshold of pain. Test subjects will be able to stop testing at any time, should they become too uncomfortable. The testing takes between 1 and 1 and a half hours, and volunteers are compensated $200 for their time.
To simulate abdominal pain, we use a thin tube placed in the rectum that inflates a small balloon to very precise and safe pressures. Our bodies interpret these pressures (in ascending order) as the need to go to the bathroom; first just a little, then with increasing urgency and eventually discomfort and pain. During these experiments, we only measure the lower threshold of pain, and stop immediately when you tell us to stop. We have significant experience using this approach and we have found it consistently informative while causing the least amount of discomfort possible. The whole thing takes about an hour and we’re paying volunteers $200 for participating. We'll ask that you skip a meal before the study visit, and perform an over-the-counter enema at the start of the visit.
$200
UC and Crohn's patients: be willing to undergo a brief proctoscopy the day of the testing visit
Healthy controls: have had a colonoscopy in the last 5 years OR be willing to undergo a brief proctoscopy the day of the testing visit
Healthy control: any diagnosed lower GI disease (such as IBS or active diverticulitis) or significant abdominal pain in the last 12 months.
Any peripheral neuropathy or neuromodulating/opioid medications
Any Autoimmune disease (except Crohn's disease or ulcerative colitis)
A Phase III De-escalation of Breast Radiation for Stage I, Hormone Sensitive, HER2 Negative Breast Cancer (PSCI# 21-098) (NRG-BR007)
This study is being done to answer the following question:Is treatment with hormonal therapy as good as the usual treatment of radiation and hormonal therapy in women with low-risk breast cancer who have had lumpectomy? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your breast cancer. The usual approach is defined as care most people get for low-risk, early stage breast cancer that is sensitive to hormones.
Pt will either have radiation therapy to the breast and take a hormonal drug for at least five years or you will only take a hormonal drug for at least five years.
The patient must have recovered from surgery with the incision completely healed and no signs of infection
The patient must have an ECOG performance status of 0 or 1
The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination
The tumor must have been determined to be HER2-negative by current ASCO/CAP guidelines
pT2 - pT4 tumors including inflammatory breast cancer
Patient had a mastectomy
Non-epithelial breast malignancies such as sarcoma or lymphoma
Paget's disease of the nipple
Smart Connected Water Bottle and Lighting Devices: A Prenatal Pilot Study
We will conduct a pilot study to test feasibility of an innovative light device and blue-light glasses for promoting better sleep and a novel, smart water bottle for proper hydration. We will also examine women’s sleep and hydration behaviors in relation to their perceptions of pain, and obtain feedback from the participants on the overall patient intervention content to reduce prescription opioid use and promote behavioral pain management strategies after delivery.
Currently recruiting pregnant women who are in their 2nd or 3rd trimester.Attend a pre-session (in person OR remote) to explain the use of the water bottle, lighting devices, activity monitors, and weight scaleUse the devices for 22 days and complete surveys in your own homeAttend a post-session (in person OR remote) to return devices and participate an interview about the last 22 days
$100
2nd or 3rd trimester
18-45
Reside around State College, PA
Diagnosed eating disorders/extreme dietary restrictions
Currently diagnosed with gestational diabetes
Currently diagnosed with pre-eclampsia
Not pregnant
Phase II Study of Bendamustine and Rituximab plus Venetoclax in Untreated Mantle Cell Lymphoma over 60 Years of Age
This study is to see if venetoclax in combination with bendamustine and rituximab chemotherapy is effective in treating people who have mantle cell lymphoma and to examine the side effects, good and bad, associated with this combination .
This study is to see if venetoclax in combination with bendamustine and rituximab chemotherapy is effective in treating people who have mantle cell lymphoma and to examine the side effects, good and bad, associated with this combination .
Must have measurable or evaluable disease as defined as a lymph node measuring >1.5 cm in any dimension or splenomegaly with spleen >15 cm in craniocaudal dimension
ECOG performance status of 0-2
Adequate organ function as measured by the criteria
Total Bilirubin ≤ 1.5x upper limit of normal (ULN) or ≤ 3x ULN with documented Gilbert’s syndrome
Should not have prior chemotherapy, radiotherapy or immunotherapy for lymphoma
Must not have received a prior allogeneic stem cell transplant or solid organ transplant (except for cornea) for any indication
Must have no active, uncontrolled infections
Must not have active hepatitis B or be chronic carriers of hepatitis B.
A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer (NRG-BR004) (PSCI# 20-136)
The purpose of this study is to compare the usual treatment plus placebo to the usual treatment plus atezolizumab. The addition of atezolizumab to the usual treatment could stabilize your cancer. This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the atezolizumab lengthens the time during and after the treatment of your cancer that you live with your cancer and it is stable. Atezolizumab is already approved by the FDA for use in non-small cell lung cancer and urinary cancer. Its use in this study is considered experimental. There will be about 600 people taking part in this study.
pt will initially get the chemotherapy drug paclitaxel or docetaxel along with trastuzumab, pertuzumab, and either placebo or atezolizumab.
Histologically confirmed adenocarcinoma of the breast with locally recurrent, unresectable disease, or metastatic disease
Adequate hematologic function within 14 days prior to randomization
Localized palliative radiation therapy is allowed for symptom management if completed 14 days or more prior to randomization
Adequate renal function determined within 14 days prior to randomization
History of exposure to cumulative doses of doxorubicin greater than 360 mg per square meter of body surface area or its equivalent
Prior treatment with mTOR inhibitors or CDK 4/6 inhibitors in combination with endocrine therapy for treatment of metastatic disease
History of asymptomatic LVEF decline to < 40% during or after prior HER2-targeted therapy
Prior treatment with CD137 agonists or immune checkpoint-blockade therapies, including antiCD40, anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies
Psychopathy and Affective Priming
This is a study which examines whether priming for fear can influence affective empathy in persons high in psychopathic traits.
Able to read and write in English
Persons under the age of 18
Human-Centric Non-Invasive Physiological Sensing System for Early Detection of Workers’ Heat Stress in the Field
This study will examine different structural designs of stretchable, skin-like sensors on the surface of human skin for workers.
There will be one in person visit;Subjects will first be asked to sit still for 3 minutes and then move their skin by the research team for another 3 minutes.
be over 18 years old
must understand English
resources from Penn State, University Park
A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients
Study of the safety of unlicensed cord blood units for stem cell transplant of children and adults.
For the treatment arm of this study you will no receive the total body radiation (TBI) as typically given before transplant. In this study you will have various research procedures such as a Blast sample at the screening part of the study, and MRD testing of your bone marrow and blood at screening and through the course of the study. Participation in the treatment arm (Non-TBI) of the study will last up to 5 years.
You are receiving unlicensed CB products from other CB banks
Muscular Dystrophy Association Neuromuscular Observational Research (MOVR) Data Hub Protocol
The Muscular Dystrophy Association (MDA) wants to collect information about individuals with neuromuscular disease to better understand the disease progression and ultimately improve the medical care, quality of life, and survival of those with neuromuscular disease. To collect this information, MDA has created a data registry called the Neuromuscular Observational Research Data Hub (referred to as the “MOVR Data Hub”). The MOVR Data Hub is a kind of database — a way of collecting and storing information.
Each person who participates in the MOVR Data Hub will have his/her information collected for as long as the person is being seen at an MDA Care Center and information is still being collected, unless and until the person requests that the information no longer be provided to the MOVR Data Hub.
Mindful Moms study
This study (Mindful Moms) is being done to understand how an 8-week app-based mindfulness program called Calm impacts breastfeeding and maternal well-being. Eligible participants will be asked to complete three online surveys (each survey will take about 20 minutes) and take part in an 8-week app-based mindfulness program. Eligible participants will also be asked to take part in one online interview that will take about 25-30 minutes once the mindfulness program is over.
Participants will take part in one of two groups: A group asked to take part in a free 8-week app-based mindfulness program on their smartphone starting when they are 36 weeks pregnant or 4 weeks after delivery. The program will teach participants about mindfulness and breathing strategies to assist with calming their mind and body. or A group asked to take part in a free 8-week app-based mindfulness program on your smartphone starting 4 weeks or 12 weeks after they deliver. The program will teach participants about mindfulness and breathing strategies to assist with calming their mind and body. Participants will also be asked to complete three online surveys (each survey will take about 20 minutes) and take part in one online interview that will take about 25-30 minutes once the mindfulness program is over.
$130
currently pregnant (12 to 34 weeks) or recently delivered (within the past 4 weeks)
intend to or are currently breastfeeding
daily access to a smartphone
willing to download a free mobile app
Satisfying Competing Task Goals While Walking on Different Paths
As we walk, we have to achieve different task goals: stay on the path, keep moving forward, maintain balance, etc. This study will test young healthy adults walking on various types of paths to determine how they negotiate achieving these various task goals. We predict that for different walking tasks, these healthy adults will make different trade-offs between which goals to achieve in a systematic and predictable way.
There will be one in-person visit lasting no more than 3 hours. Participants will be asked to perform some basic vision, reaction time, and balance tasks. Participants will then be asked to walk on a treadmill in a virtual environment under a variety of conditions where the visual scene and/or paths being walked on change from trial to trial.
$20
Body Mass Index (BMI) ≥ 18 and ≤ 30
Blood pressures with systolic < 140 and diastolic < 90
Corrected visual acuity (Snellen chart) ≥ 20/40 with both eyes open
Able to walk un-assisted for at least 5 minutes without shortness of breath, chest pain, or joint pain in the legs, neck, or back
Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification for Higher Genomic Risk with Radiation (NRG-GU009) (PSCI# 20-141)
This study is being done to answer the following questions: If you have high risk prostate cancer, a low gene risk score and plan to receive radiation therapy, is a shorter hormone therapy treatment as effective at controlling your cancer compared to the usual 24 month hormone therapy treatment? If you have high risk prostate cancer, a high gene risk score and plan to receive radiation therapy, does adding two new hormone therapy drugs to the usual treatment increase the length of time without your prostate cancer spreading as compared to the usual treatment?We are doing this study because we want to find out if these approaches are better, similar, or worse than the usual approach for your type of prostate cancer. The usual treatment is defined as the care most people get for prostate cancer.
This study is being done to answer the following questions:If you have high risk prostate cancer, a low gene risk score and plan to receive radiation therapy, is a shorter hormone therapy treatment as effective at controlling your cancer compared to the usual 24 month hormone therapy treatment?If you have high risk prostate cancer, a high gene risk score and plan to receive radiation therapy, does adding two new hormone therapy drugs to the usual treatment increase the length of time without your prostate cancer spreading as compared to the usual treatment?We are doing this study because we want to find out if these approaches are better, similar, or worse than the usual approach for your type of prostate cancer. The usual treatment is defined as the care most people get for prostate cance
High-risk disease
ECOG Performance Status of 0-2 within 120 days prior to registration
Adequate hematologic function within 120 days prior to registration
Adequate hepatic function within 120 days prior to registration
Prior systemic chemotherapy within ≤3 years prior to registration
Current use of 5-alpha reductase inhibitor
Didanosine (DDI) antiretroviral therapy is not permitted
History of seizure disorder or current severe or unstable angina
The Blended4Blues Study
An intervention using an internet-based platform for coping and mood difficulties. Participants will be able to use cognitive-behavioral therapy (CBT) based online self-help modules over the course of a 10-week program.
Participants will engage with online materials on a weekly basis for 10 weeks.
$25
U.S. resident currently residing in the United States
Fluent in the English language in terms of speaking, listening, reading, and writing.
Aged 18-19 years
Presence of depressive symptoms as measured by a score ≥ 10 on the QIDS-17-SR
Unable to speak, read, listen, and write English fluently.
Do not meet inclusion criteria for clinical depression on the QIDS-17-SR, i.e., score ≥ 10
Does not fulfill DSM-5 Criteria for MDE on the MINI Clinical Interview.
Expressed suicidal ideation defined as score >1 on the suicide ideation item on the PHQ-9, and/or on the MINI.
A qualitative exploration of rurality, physical activity, and intervention preferences among older residents in Pennsylvania
This study will use interviews to explore to explore perceptions of rurality, physical activity behaviors and physical activity intervention preferences among rural older adults who live in Pennsylvania
Currently residing in Pennsylvania
Able to speak, read, and write in English
Not currently residing in Pennsylvania
Not able to speak, read, and write in English
Penn State SELF - Student Engagement, Learning and Flourishing
Substance misuse is a leading national problem, with young adults at high risk. We aim to develop a university resource that elucidates biobehavioral underpinnings of problematic student substance use at University Park campus. This initiative would inform services needed, provide engaged learning opportunities, connect with faculty, and catalyze high-impact, interdisciplinary research. In addition to this primary rationale, this study will allow us to capture detailed information about other critical student experiences such as food and housing insecurity, experiences of discrimination, and daily health practices to prevent the transmission of COVID-19. Participants will be asked to take a baseline survey followed by a 21- daily diary protocol (brief 5 minute survey each day for 21 days. For more information or to register interest in participating please see: https://projectself.psu.edu/register-your-interest/
Enrolled at UP
18-24 years old
Part-time students
Students located in the EEA
Older than 24
No graduate students
Identifying views of Military Veterans Regarding Contemporary War and Conflict Reporting
This study will involve surveying and interviewing US military veterans and non-veterans regarding their perceptions of the quality, accuracy, and themes of contemporary war and conflict reporting.
Military Veteran
Current Member of the Military
Non-Military Civilians
Attention for Neoteny Among Distractors
This is a reaction time study where participants need to detect a stimuli among distractor stimuli. This study will examine whether physical immaturity (also called neoteny) has preferential attentional mechanisms by asking participants to detect neotenous stimuli among other neotenous stimuli and non-neotenous stimuli as distractors.
Opens to males and females
Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer (PSCI# 21-217) (NRG-GU010)
The purpose of this study is to use the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient’s cancer aggressiveness. The study will test your tumor tissue for many different genes that all together indicate the risk of your cancer spreading; this is called the Decipher risk score. If you have a higher Decipher risk score, you will be assigned to the part of the study that compares the use of 6 months of hormone therapy and radiation treatment (usual treatment) to the use of darolutamide (BAY 1841788) plus the usual treatment. The purpose of this study is to determine whether the additional drug can reduce the chance that your cancer will come back and spread.
The purpose of this study is to use the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient’s cancer aggressiveness.The study will test your tumor tissue for many different genes that all together indicate the risk of your cancer spreading; this is called the Decipher risk score.If you have a higher Decipher risk score, you will be assigned to the part of the study that compares the use of 6 months of hormone therapy and radiation treatment (usual treatment) to the use of darolutamide (BAY 1841788) plus the usual treatment. The purpose of this study is to determine whether the additional drug can reduce the chance that your cancer will come back and spread.
ECOG Performance Status of 0-2 within 120 days prior to registration;
For patients with a history of hepatitis C virus (HCV) infection must have been treated and cured.
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months
Previous bilateral orchiectomy
Prior radiotherapy to the prostate/pelvis region that would result in overlap of radiation therapy fields.
Active testosterone replacement therapy; any replacement therapy must be stopped at least 30 days prior to registration
Inability to swallow oral pills.
A Randomized Controlled Pilot Study of the Use of Cannabidiol in the Management of Endometriosis Pain
We are looking to conduct a study looking at the effects of cannabidiol (CBD) in patients with endometriosis. We believe that CBD will improve both pain and quality of life. The study will last a total of 12 weeks and involve several onsite visits in addition to daily pain assessments.
There will be five in person visitsblood will be drawn at all of these visits
$175
Diagnosed with endometriosis by surgical diagnosis with direct visualization and/or histopathologic confirmation of endometriosis
Women with chronic daily opioid use ( > 14 days / month)
Women that are currently using Cannabis based products
Non-English speaking or inability to read and understand English
Using Exercise to Relieve Arthralgia (Joint Pain) and Improve AI Adherence in Older Survivors (REJOIN): A Pilot Study
Briefly, the purpose of this study is to use a self-management approach (combining education and exercise) to help older breast cancer survivors manage joint pain, a common side effect of aromatase inhibitors (AIs), a medication used to reduce hormones that might increase risk of recurrence and mortality following primary cancer treatment. We believe that reducing joint pain might help survivors take their medication longer and thus improve survival outcomes, compared to standard care.
Attend 4 in person visits, blood will be drawn at each visit.Complete physical function tests and surveys.Wear accelerometer for 7 days following each visit.Randomly selected participants will attend group exercise sessions twice a week for eight weeks via video call and record exercise activities between visits.
$160
Female
Breast Cancer Survivor
Preparing to Start AI medication
ER+ diagnosis
Gross Cognitive Impairment
Recent Joint Surgery
Cardiac event/Stroke within last 6 months
Not willing to come to HMC for Exercise Sessions
The association between perceived parenting styles, intolerance of uncertainty, and anxiety among young adults
This study aims to understand the association between young adults' perceived parenting, intolerance of uncertainty, and trait anxiety. Participant will be asked to complete a questionnaire that aims to answer the environment and parenting beliefs around which they were brought up, and if they face stressors and anxieties associated with them. This is a correlational study
Geographical location: USA
All genders
All ethnicities
Individuals over 34 years
Individuals residing outside USA
The effects of local negative pressure on forearm and skin blood flow in humans
This study continues our exploration into the mechanisms underlying the control of blood flow. During the experiments, we noninvasively measure skin blood flow (SkBF) and forearm blood flow (FBF) with a FLPI and venous occlusion plethysmography (VOP), respectively. The FLPI uses a low energy laser to measure SkBF. VOP uses blood pressure cuffs on the upper arm and wrist, and an elastic strain gauge encircling the forearm between the cuffs to measure the change in forearm-circumference over time from which we calculate FBF. For each experiment, we collect SkBF and FBF data for a 20-minute baseline, expose the skin of the forearms to negative pressure and then collect SkBF and FBF data for an additional 30-90 minutes. Each subject participates in 2 experiments that differ only in the protocol for the application of negative pressure (i.e. continuous, pulse).
•Individuals that use nicotine-containing products
Illicit or recreational drug-use
•Taking corticosteroids, anticoagulants, NSAIDS, or blood thinners
Pregnancy
TMIST_EA1151
This study is being done to answer the following question:Can tomosynthesis mammography, three-dimensional x-ray imaging of the breast, lower your chance of developing life-threatening breast cancer through routine screening compared with digital mammography, two-dimensional x-ray imaging of the breast?We are doing this study because we want to find out which of the two usual approaches to breast cancer screening are better in the early detection of life-threatening breast cancers.
Patients must be scheduled for, or have intent to schedule, a screening mammogram.
Patients must be able to tolerate digital breast tomosynthesis and fullfield digital mammographic imaging required by protocol.
Patients must be willing and able to provide a written informed consent.
Patients must not have new symptoms or signs of benign or malignant breast disease
Patients must not have had a screening mammogram within the last 11 months prior to date of randomization.
Patients must not have previous personal history of breast cancer including ductal carcinoma in situ
Patients must not currently have breast enhancements (e.g., implants or injections).
Breaking the Model Minority Mold: Storying the Experiences of Asian Americans labeled dis/abled
This is a qualitative study that will examine the educational experiences of Asian American individuals who have been labeled as dis/abled or academically struggling at some point throughout their educational career. The study will focus on the narrated stories and discussions from the participants as they reflect on various moments from their education.
Identify or have been labeled as disabled
Received the majority of K-12 education within the United States
Over the age of 18
Received majority of K-12 education outside of the United States
Do not identify as Asian American